Friday, March 21, 2025
spot_img

The Ensign Group, Inc. Declares Quarterly Dividend of $0.0625 Per Share

SAN JUAN CAPISTRANO, California, March 20, 2025 (GLOBE NEWSWIRE) — The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it has declared a quarterly cash dividend of $0.0625 per share of Ensign common stock, payable on or before April 30, 2025, to shareholders of record as of March 31, 2025.

Ensign has been a dividend-paying company since 2002.

About Ensignâ„¢

The Ensign Group, Inc.’s independent operating subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 340 healthcare facilities in Alabama, Alaska, Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Oregon, South Carolina, Tennessee, Texas, Utah, Washington and Wisconsin. More information about Ensign is available at http://www.ensigngroup.net.

Contact Information

The Ensign Group, Inc., (949) 487-9500, [email protected]

SOURCE: The Ensign Group, Inc.

Powered by SlickText.com

Hot this week

FDA Approves New Prostate Cancer Imaging Agent Gozellix®

MELBOURNE, Australia and INDIANAPOLIS, March 21, 2025 ...

Ordinær generalforsamling 2025

Indkaldelse til ordinær generalforsamling den 23. april 2025 er...

Net Asset Value(s)

FORESIGHT VENTURES VCT PLC LEI: 213800R88MRC4Y3OIW86 NAV ANNOUNCEMENT21 MARCH...

Topics

FDA Approves New Prostate Cancer Imaging Agent Gozellix®

MELBOURNE, Australia and INDIANAPOLIS, March 21, 2025 ...

Ordinær generalforsamling 2025

Indkaldelse til ordinær generalforsamling den 23. april 2025 er...

Net Asset Value(s)

FORESIGHT VENTURES VCT PLC LEI: 213800R88MRC4Y3OIW86 NAV ANNOUNCEMENT21 MARCH...

Net Asset Value(s)

                 WisdomTree Issuer plc – Daily Fund Prices 20-March-25        WisdomTree...

Chimerix Reports Fourth Quarter and Year End 2024 Financial Results

New Drug Application (NDA) for Dordaviprone as Treatment for...
spot_img

Related Articles

Popular Categories

spot_img